CDK19
MOLECULAR TARGETcyclin dependent kinase 19
CDK19 (cyclin dependent kinase 19) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CDK19
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | imatinib | 5.47 | 236 |
| 2 | alvocidib | 4.52 | 91 |
| 3 | foretinib | 4.34 | 76 |
| 4 | doramapimod | 4.06 | 57 |
| 5 | quizartinib | 3.99 | 53 |
| 6 | midostaurin | 3.85 | 46 |
| 7 | vatalanib | 3.69 | 39 |
| 8 | bms 387032 | 3.47 | 31 |
| 9 | linifanib | 3.33 | 27 |
| 10 | at 7519 | 3.33 | 27 |
| 11 | plx 4720 | 2.71 | 14 |
| 12 | ast 487 | 2.56 | 12 |
| 13 | cp 724714 | 2.56 | 12 |
| 14 | raf 265 | 2.48 | 11 |
| 15 | sel 120 free base | 1.95 | 6 |
| 16 | Sorafenib | 1.10 | 2 |
| 17 | alsterpaullone | 0.69 | 1 |
About CDK19 as a Drug Target
CDK19 (cyclin dependent kinase 19) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented CDK19 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CDK19 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.